AbbVie
ABBV
#27
Rank
NZ$851.74 B
Marketcap
NZ$482.00
Share price
-0.56%
Change (1 day)
19.73%
Change (1 year)

The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โ€œABBVโ€.

AbbVie (ABBV) - Cash on Hand

Cash on Hand as of June 2026 : NZ$11.73 Billion

According to AbbVie's latest financial reports the company has NZ$11.73 Billion in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

AbbVie - Cash on Hand chart (from 2011 to 2026)

Cash on Hand by year

Year Cash on Hand Change
2025-12-31NZ$9.07 B-7.84%
2024-12-31NZ$9.84 B-51.4%
2023-12-31NZ$20.26 B39.42%
2022-12-31NZ$14.53 B1.01%
2021-12-31NZ$14.39 B22.47%
2020-12-31NZ$11.75 B-80.18%
2019-12-31NZ$59.28 B393.28%
2018-12-31NZ$12.01 B-12.81%
2017-12-31NZ$13.78 B48.65%
2016-12-31NZ$9.27 B-24.51%
2015-12-31NZ$12.28 B14.93%
2014-12-31NZ$10.68 B-11.24%
2013-12-31NZ$12.04 B24.19%
2012-12-31NZ$9.69 B1058.81%
2011-12-31NZ$0.83 B5890.66%
2010-12-31NZ$13.96 M

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
Pfizer
PFE
NZ$20.89 B 78.08%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$15.98 B 36.25%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$24.98 B 112.95%๐Ÿ‡บ๐Ÿ‡ธ USA
Biogen
BIIB
NZ$2.29 B-80.44%๐Ÿ‡บ๐Ÿ‡ธ USA
Gilead Sciences
GILD
NZ$5.67 B-51.61%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$19.76 B 68.47%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
NZ$8.87 B-24.37%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
NZ$7.35 B-37.35%๐Ÿ‡ฌ๐Ÿ‡ง UK
Neurocrine Biosciences
NBIX
NZ$0.69 B-94.07%๐Ÿ‡บ๐Ÿ‡ธ USA